( of insulin producing beta cells by the...)Revolutionary Immunologic Data Explains Function of Diamyd Diabetes,Vaccine,Health

of insulin producing beta cells by the immune system (the so-called “autoimmune attack”). These immunological markers remained upregulated even 15 months after the first injection, while patients that received placebo showed a downregulation of the same markers over time. Accumulation of scientific evidence has long pointed to GAD65, the active ingredient of Diamyd®, as a possible “immunomodulator” that could prevent the immune system from destroying the insulin producing beta cells.

Immunological Findings Consistent with Expectations Explains Positive Clinical Results
Professor Ludvigsson explained that the immunological data provided direct confirmation of the positive clinical results obtained in August 2006. They demonstrated that treatment close to disease onset provided a better clinical effect than a later in time administration of the vaccine. The new immunological findings indicate that virtually all Diamyd® treated patients, regardless of disease duration, responded immunologically, but that the clinical effect of arresting the autoimmune attack that destroys beta cells close to disease onset is superior to a later intervention when the patient’s beta cells have been almost totally destroyed.

“This may be a breakthrough in diabetes research”, says Professor Johnny Ludvigsson. “There is no doubt that the GAD-vaccine has had positive effects. And it is a treatment that is very simple and without side effects. We have previously reported that the earlier a patient is treated with Diamyd®, the better are the chances that the endogenous insulin production will be preserved. Now we can state that the treatment may be relevant also at a later stage as the immunological effect observed may be a prerequisite to allow beta cell regeneration or transplanted islets or stem cells to thrive without being destroyed by recurrent autoimmune attacks.”

Potentially Groundbreak
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Mild Asthma, a Revolutionary Therapy from Italian Research
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
4. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
5. Data Suggest Cymbalta Improved Functioning in Patients with Generalized Anxiety Disorder
6. Early Results of the CellCept Spare the Nephron Study Examine Kidney Function
7. EPIX Pharmaceuticals Announces Statistically Significant Results in Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug Candidate
8. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
9. Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of CERE-120 Demonstrating Improved Motor Function in Parkinsons Patients
10. Heart Attack Patients Treated With Novel Stem Cell Therapy Experience Significant Improvement in Heart and Lung Function
11. BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality